Dong-A acquires South Korean naftopidil rights
This article was originally published in Scrip
Executive Summary
Japan's Asahi Kasei has licensed its benign prostatic hyperplasia therapy, naftopidil, to Dong-A Pharmaceutical for South Korea. The company has gained exclusive rights in its home market to develop and commercialise the alpha-1 antagonist, which was launched as Flivas in Japan in 1999. The molecule acts to relax prostate and urethral smooth muscle, and is also in Japanese clinical development for neurogenic bladder. Dong-A already has a presence in the urology sector through Zydena (udenafil), its PDE5-inhibitor for erectile dysfunction.